N/A N=96 Improving Sleep in Veterans and Their CGs
Sleep Quality
Primary: Subjective Sleep Quality — 8.41; 8.31; 5.98; 8.63 units on a scale — p=<.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=354 Monthly And Twice Monthly Subcutaneous Dosing Of PF-04950615 (RN316) In Hypercholesterolemic Subjects On A Statin
Hypercholesterolemia
Primary: Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12 — -2.6; -36.9; -47.6; -56.0 milligram per deciliter (mg/dL) — p=<0.001
N/A N=257 Study to Promote Weight Loss in Primary Care Practices
Obesity
Primary: Weight — 105.8; 109.4; 102.07; 101.23 kg — p=<0.01
Phase 3 N=689 Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes
Diabetes · Diabetes Mellitus, Type 2
Primary: Change From Baseline in HbA1c — 7.96; 7.89; 6.63; 6.59 Percentage of glycosylated haemoglobin
N/A N=51 Impact of Prophylactic High Flow Nasal Oxygen in Post-Operative Thoracic Surgical Patients
Post-operative Pulmonary Complications
Primary: Number of Participants With Post-operative Pulmonary Complications — 1; 2 Participants — p=0.680
N/A N=82 Patient Response to Spinal Manipulation
Low Back Pain
Primary: Patient-Centered Outcome Measurement Mean Change After 6 Weeks (VAS, RMDQ) — 20.1; 4.8 units on a scale (see description above)
N/A N=4 Study of Skin and Muscle Parameters Using a Skin Sensor
Skin Wounds
Primary: Measure Temperature at 3 Time Points — 29.89; 31.13; 31.87; 32.02 Degrees Celsius — p=<0.0001
Phase 2 N=187 A Study of Effectiveness and Safety of CNTO 136 in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy
Arthritis, Rheumatoid
Primary: Percentage of Participants With an American College of Rheumatology (ACR) 50 Response at Week 12 (Part B) — 3.3; 26.7; 23.3; 26.7 Percentage of Participants — p=0.026
N/A N=288 Way to Be Active IV (Framing vs Incentives)
Sedentary Lifestyle
Primary: Proportion of Days a Participant Walks 7000 Steps or More — 0.30; 0.27; 0.45; 0.38 Mean proportion
Phase 3 N=38 A Phase 3 Study of Fluvoxamine (SME3110) in Pediatric/Adolescent Patients With Obsessive Compulsive Disorder
Obsessive Compulsive Disorder
Primary: Mean Change From Baseline in the Japanese Children's Yale-Brown Obsessive Compulsive Scale 10-item Total Score at the End of Treatment in the First Phase — -10.5; -6.6…
Phase 2 N=52 Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration
Prostate Cancer · Prostatic Neoplasms
Primary: Percentage of Patients Free of Progression and Without Symptomatic Deterioration — 24; 9 percentage of Participants
Phase 2 N=64 A Study for Participants With Small-Cell Lung Cancer
Small Cell Lung Cancer
Primary: Part A: Percentage of Participants Achieving an Overall Response (Overall Response Rate) — 2.6 percentage of participants
Phase 3 N=3,602 Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction
Myocardial Infarction
Primary: Pharmacology Arm - Major Adverse Ischemic Cardiac Events and Major Bleeding Events — 166; 218 Participants
Phase 2 N=50 Ranolazine Among Unrevascularized Chronic Stable Angina Patients
Angina
Primary: Seattle Angina Questionnaire Score Change From Baseline to 16 Weeks — 48; 50; 40; 60 units on a scale — p=>0.05
Phase 2 N=84 GSK1322322 Versus Linezolid in the Treatment of Acute Bacterial Skin and Skin Structure Infection
Skin Infections, Bacterial
Primary: Number of Participants With Any Adverse Events (AE) and Serious Adverse Events (SAE) — 49; 20; 1; 1 Participants